Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia
Trial ID or NCT#
NCT02165397
Status
NOT RECRUITING
Purpose
The purpose of this study is to evaluate the safety and efficacy of ibrutinib in combination with rituximab in participants with Waldenström's macroglobulinemia (WM).
Official Title
iNNOVATE Study: A Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study of Ibrutinib or Placebo in Combination With Rituximab in Subjects With Waldenström's Macroglobulinemia
Investigator(s)
Daniel Rubin
Lauren Maeda
Hematologist,
Lymphoma specialist,
Hematologist-Oncologist
Clinical Associate Professor, Medicine - Oncology
Ranjana H Advani
Lymphoma specialist,
Hematologist-Oncologist
Saul A. Rosenberg, MD, Professor of Lymphoma
Contact us to find out if this trial is right for you.
Contact
Cancer Clinical Trials Office
650-498-7061
View on ClinicalTrials.gov
